Relief Therapeutics Holding AG (RLFTF)

[Uncle Gee Gee]

Yes... also... Javitt stated they have more data from the open label studies that is showing similar results. So we should expect the 144 results to mimic the ones below, and I would say this is such a very large difference, that we are expecting to blow the required statistical significance out of the water.

Results

• 45 patients enrolled - had the highest possible risk for mortality
...21 were selected for Aviptadil in June & July
...24 were selected for the control group from May - Aug

• 19 of 21 (90%) Aviptadil patients survived to day 28
...4 of 24 (19%) in the control group

• 4 of 5 (80%) Aviptadil patients on ECMO were removed
...3 of 13 (23%) in the control group

• 15 of 16 (94%) Aviptadil patients on vent were removed
...1 of 11 (9%) in the control group

• 10 Aviptadil patients returned home/care facility
...2 in the control group

• 15 of 21 (71%) Aviptadil patients had 100+ point improvement in oxygenation
...4 of 30 (13%) in the control group

Aviptadil Patient Stats

• 9-Fold advantage of survival P<.001
• 9-Fold advantage of recovery from respiratory failure P<.001
• 8 times more likely to return home or a care facility on Aviptadil
• 3-fold improvement in oxygenation
• 17 of 21 saw improvement in both lungs. The other 2 saw improvement in 1 lung
• 2 Patients developed hypotension - treated
• 4 Patients developed diarrhea - treated

Important Note: At ICU admission, the “Rothman index” and “SOFA score” for Aviptadil-treated patients was significantly worse than for control patients. SOFA measures organ failure and Rothman predicts mortality. That means Aviptadil patients were coincidentally already at a huge disadvantage.